Since we described a significant enrichment of HG-BCL w/DH cases in the DE-Ox high subset, we then extended our cell line panel including different DH DLBCL models, and validated HTS results by cell-titer-glo assay using the CHK1/2 inhibitor Prexasertib. This evidence concerns the gene CHEK1 and diffuse large B-cell lymphoma.